Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Allergan's Migraine Prevention Drug Meets Primary Endpoints in Ph Iib/III Study
Allergan's Migraine Prevention Drug Meets Primary Endpoints in Ph Iib/III Study
Allergan's Migraine Prevention Drug Meets Primary Endpoints in Ph Iib/III Study
Submitted by
CP Staff
on June 11, 2018 - 9:15am
Source:
CP Wire
News Tags:
migraines
Allergan
atogepant
Headline:
Allergan's Migraine Prevention Drug Meets Primary Endpoints in Ph Iib/III Study
snippet:
Atogepant met primary endpoint for all doses and dose regimens
Atogepant was well tolerated and there was no signal of hepatotoxicity with daily administration over 12 weeks
Allergan plans to rapidly move into next phase of development
Do Not Allow Advertisers to Use My Personal information
